Skip to main content

Advertisement

SpringerLink
Log in

Experience with Newer Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer

  • Urothelial Cancer (A Sagalowsky, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

The definitive treatment for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who fail to respond to intravesical bacillus Calmette-Guérin (BCG) is cystectomy. However, many patients who experience recurrence after BCG are either poor operative candidates or refuse surgery due to the long-term impact on their quality of life. In the last decade, there has been an increased interest in alternative intravesical therapies, and several novel chemotherapeutics have emerged as promising agents for high-risk NMIBC patients unable or unwilling to undergo cystectomy. Additionally, extended treatment regimens with combined induction and maintenance therapy have been investigated, and may increase the durability of response to these new agents, as has been shown for conventional intravesical therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  2. Rubben H, Lutzeyer W, Fischer N, et al. Natural history and treatment of low and high risk superficial bladder tumors. J Urol. 1988;139:283–5.

    PubMed  CAS  Google Scholar 

  3. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180–3.

    PubMed  CAS  Google Scholar 

  4. Lamm DL, Reichert DF, Harris SC, Lucio RM. Immunotherapy of murine transitional cell carcinoma. J Urol. 1982;128:1104–8.

    PubMed  CAS  Google Scholar 

  5. Nadler R, Luo Y, Zhao W, et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. Clin Exp Immunol. 2003;131:206–16.

    Article  PubMed  CAS  Google Scholar 

  6. Ratliff TL, Gillen D, Catalona WJ. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987;137:155–8.

    PubMed  CAS  Google Scholar 

  7. Ratliff TL, Ritchey JK, Yuan JJ, et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993;150:1018–23.

    PubMed  CAS  Google Scholar 

  8. Mungan NA, Witjes JA. Bacille Calmette-Guerin in superficial transitional cell carcinoma. Br J Urol. 1998;82:213–23.

    Article  PubMed  CAS  Google Scholar 

  9. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964–9.

    Article  PubMed  Google Scholar 

  10. Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 2004;64:3386–90.

    Article  PubMed  CAS  Google Scholar 

  11. Jones J, Campbell S. Non-muscle-invasive bladder cancer (Ta, T1, and CIS). In: Wein A, Kavoussi L, Novick A, Partin A, Peters C, editors. Campbell-Walsh urology, 9 edn, vol. 3. Philadelphia: Saunders; 2006. p. 2447–67.

    Google Scholar 

  12. Krege S, Giani G, Meyer R, et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating clinics. J Urol. 1996;156:962–6.

    Article  PubMed  CAS  Google Scholar 

  13. Morales A. Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. J Urol. 1984;132:457–9.

    PubMed  CAS  Google Scholar 

  14. Catalona WJ, Hudson MA, Gillen DP, et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1987;137:220–4.

    PubMed  CAS  Google Scholar 

  15. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009;23:675–80.

    Article  PubMed  CAS  Google Scholar 

  16. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol. 2003;169:1706–8.

    Article  PubMed  CAS  Google Scholar 

  17. Lambert EH, Pierorazio PM, Olsson CA, et al. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007;100:33–6.

    Article  PubMed  Google Scholar 

  18. Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol. 2009;181:1040–5.

    Article  PubMed  Google Scholar 

  19. Malmstrom PU, Wijkstrom H, Lundholm C, et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol. 1999;161:1124–7.

    Article  PubMed  CAS  Google Scholar 

  20. Addeo R, Caraglia M, Bellini S, et al. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol. 2009;28:543–8.

    Article  PubMed  Google Scholar 

  21. Friedrich MG, Pichlmeier U, Schwaibold H, et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol. 2007;52:1123–9.

    Article  PubMed  CAS  Google Scholar 

  22. Greenberg RE, Bahnson RR, Wood D, et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology. 1997;49:471–5.

    Article  PubMed  CAS  Google Scholar 

  23. Patterson AL, Greenberg RE, Weems L, et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology. 2000;56:232–5.

    Article  PubMed  CAS  Google Scholar 

  24. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163:761–7.

    Article  PubMed  CAS  Google Scholar 

  25. • Dinney CP, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin. Urol Oncol 2012, doi:10.1016/j.urolonc.2012.04.010. The authors report the long-term recurrence data from a combined phase II/III trial of intravesical valrubicin.

  26. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol. 1985;57:680–85.

  27. Heney NM. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa. Urology. 1985;26:27–9.

    Article  PubMed  CAS  Google Scholar 

  28. Heney NM, Koontz WW, Barton B, et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol. 1988;140:1390–3.

    PubMed  CAS  Google Scholar 

  29. Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin N Am. 1992;19:529–39.

    CAS  Google Scholar 

  30. Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology. 2005;66:726–31.

    Article  PubMed  Google Scholar 

  31. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24:2729–34.

    Article  PubMed  CAS  Google Scholar 

  32. Serretta V, Galuffo A, Pavone C, et al. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: phase I-II study on marker lesions. Urology. 2005;65:65–9.

    Article  PubMed  Google Scholar 

  33. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002;20:3193–8.

    Article  PubMed  CAS  Google Scholar 

  34. Grossman HB, O’Donnell MA, Cookson MS, et al. Bacillus calmette-guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol. 2008;10:281–9.

    PubMed  Google Scholar 

  35. •• Jones G, Cleves A, Wilt TJ, et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev. 2012;1:CD009294. This is a comprehensive review of randomized controlled trials of intravesical gemcitabine. It includes 704 patients from six studies.

    PubMed  Google Scholar 

  36. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441–5.

    PubMed  CAS  Google Scholar 

  37. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394–8.

    PubMed  CAS  Google Scholar 

  38. Perdona S, Di Lorenzo G, Cantiello F, et al. Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial. Anticancer Drugs. 2010;21:101–6.

    Article  PubMed  CAS  Google Scholar 

  39. Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of BCG. 2012 American Urological Association Annual Meeting; 2012. May 22nd; Atlanta, Georgia, 2012.

  40. Calabro F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol. 2002;20:158–66.

    PubMed  CAS  Google Scholar 

  41. Song D, Wientjes MG, Au JL. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol. 1997;40:285–92.

    Article  PubMed  CAS  Google Scholar 

  42. McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24:3075–80.

    Article  PubMed  CAS  Google Scholar 

  43. Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology. 2009;75:134–7.

    Article  PubMed  Google Scholar 

  44. Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy. BJU Int. 2009;104:1098–102.

    Article  PubMed  CAS  Google Scholar 

  45. Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel in the management of non-muscle-invasive bladder cancer (NMIBC) refractory to BCG therapy. 2012 American Urological Association Annual Meeting; 2012. May 22nd; Atlanta, Georgia, 2012.

  46. • Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with Intravesical Docetaxel in the management of recurrent nonmuscle invasive bladder cancer after previous Bacillus Calmette-Guerin therapy. J Urol. 2012, doi:10.1016/j.juro.2012.10.068. This is the largest published series of intravesical docetaxel. It includes long-term recurrence and survival outcomes as well as the impact of maintenance docetaxel on delaying recurrence.

  47. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol. 2001;166:1296–9.

    Article  PubMed  CAS  Google Scholar 

  48. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11:4136–43.

    Article  PubMed  CAS  Google Scholar 

  49. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803.

    Article  PubMed  CAS  Google Scholar 

  50. McKiernan JM, Barlow LJ, Laudano MA, et al. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer. J Urol. 2011;186:448–51.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

Dr. Mitchell Benson received a Departmental Grant for Urologic Oncology Research from the T.J. Martell Foundation.

Dr. LaMont Barlow reported no conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. Department of Urology, Herbert Irving Comprehensive Cancer Center, Herbert Irving Pavilion, Columbia University Medical Center, 11th Floor 161 Fort Washington Ave., New York, NY, 10032, USA

    LaMont J. Barlow & Mitchell C. Benson

Authors
  1. LaMont J. Barlow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell C. Benson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to LaMont J. Barlow.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barlow, L.J., Benson, M.C. Experience with Newer Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer. Curr Urol Rep 14, 65–70 (2013). https://doi.org/10.1007/s11934-013-0312-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-013-0312-2

Keywords

Search

Navigation